Two Sigma Advisers’s Foghorn Therapeutics FHTX Stock Holding History

Two Sigma Advisers’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,400	Closed	-$56.2K	–	770
2025 Q4	$56.2K	Buy	+10,400	New	+$47.1K	﹤0.01%	2278

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Two Sigma Advisers's FHTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Foghorn Therapeutics (FHTX) in Q1 2026, closing a stake of 10,400 shares — an estimated $56.2K sold.

Two Sigma Advisers first reported a position in FHTX in Q4 2025 and held it in 1 quarter. The position peaked at $56.2K in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

Two Sigma Advisers reported no remaining Foghorn Therapeutics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 10,400 Foghorn Therapeutics shares in Q1 2026, an estimated $56.2K.
Two Sigma Advisers first reported a position in Foghorn Therapeutics in Q4 2025 and held it in 1 quarter.
Two Sigma Advisers's Foghorn Therapeutics position peaked at $56.2K in Q4 2025.
105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.